Spire: Turn Up The Heat Of Your Portfolio's Returns
Spire Inc. offers a compelling blend of quality, attractive valuation, and consistent dividend growth, nearing Dividend Aristocrat status. SR's primary growth drivers are the Piedmont Natural Gas acquisition and successful rate cases, supporting 7.5% EPS growth this year and 5%–7.5% long term. With a 3.8% yield, 4.8% five-year dividend CAGR, and a payout ratio near 63%, SR targets sustainable 5% dividend growth ahead.
Here's Why Spire (SR) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Spire (SR) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Spire Inc. (SR) Q1 2026 Earnings Call Transcript
Spire Inc. (SR) Q1 2026 Earnings Call Transcript
Spire's Q1 Earnings Higher Than Estimates, Revenues Rise Y/Y
SR reports stronger-than-expected Q1 results, with rising revenues, improved operating income and higher earnings across key segments.
Spire (SR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Spire (SR) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Spire (SR) Q1 Earnings and Revenues Beat Estimates
Spire (SR) came out with quarterly earnings of $1.77 per share, beating the Zacks Consensus Estimate of $1.62 per share. This compares to earnings of $1.34 per share a year ago.
Spire to Report Q1 Earnings: What's in Store for the Stock?
SR is likely to report Q1 earnings results on Feb. 3, with new rates, lower interest costs and storage expansion in focus, even as higher O&M expenses loom.
Spire Healthcare attracts credible PE interest and sparks valuation debate
Spire Healthcare Group Plc's (LSE:SPI) confirmation that it is in preliminary talks with Bridgepoint and Triton has sharpened focus on the company's valuation as speculation builds around a potential bid. Analysts at Panmure Liberum and Peel Hunt both welcomed the update, seeing the named suitors as credible and the discussions as evidence of genuine interest.
Spire Healthcare jumps after revealing talks with private equity firms
Shares in Spire Healthcare Group Plc (LSE:SPI) jolted 16% higher to 206p after the FTSE 250-listed company said it is in talks with Bridgepoint Advisers and Triton Investment Advisers following the launch of a strategic review in September. The talks are at a preliminary stage, the private hospital operator said, with no certainty that an offer will be made or on what terms.
Spire Healthcare shares climb after confirming talks with buyout firms
Shares of Spire Healthcare surged 17% on Monday after the British private hospital group confirmed over the weekend it was in preliminary talks with multiple buyout firms including Bridgepoint and Triton to "explore strategic options".
Spire Global: Undervalued, Seems Geared For 2026 Growth Strategy
Spire Global targets over 30% revenue growth in 2026, leveraging strong government and commercial contract momentum and a robust $200M backlog. SPIR's divestiture of its maritime business caused a near-term revenue dip, but management expects normalization and a pivot to core data and analytics services. Despite recent operating losses, SPIR maintains a strengthened balance sheet with $96.8M in cash and no debt, aiming for EBITDA and cash flow breakeven by 4Q26.
